Benefit-Risk Assessment of LeflunomideAn Appraisal of Leflunomide in Rheumatoid Arthritis 10 Years After Licensing

被引：0
|
作者：
Nicola Alcorn
Sarah Saunders
Rajan Madhok
机构：
[1] Glasgow Royal Infirmary,The Centre for Rheumatic Diseases
来源：
Drug Safety | 2009年 / 32卷
关键词：
Rheumatoid Arthritis; Infliximab; Interstitial Lung Disease; Rheumatol; Sulfasalazine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Evidence is accumulating for the early sustained usage of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis. Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998. Postmarketing surveillance, case reports and observational studies have highlighted less common or unexpected adverse events. Therefore, it is appropriate that we review the benefit-risk profile of leflunomide after 10 years of widespread usage. A wide-based search of relevant literature was performed to formulate this assessment.
引用
收藏
页码：1123 / 1134
页数：11
相关论文
共 23 条
  • [21] Sicherheit der Biologika: Ergebnisse aus den RegisternMortalität/Safety-Benefit-RelationThe safety of biologicsA risk-benefit assessment of treating rheumatoid arthritis with biologics based on registry data on mortality
    O. Sander
    Zeitschrift für Rheumatologie, 2010, 69 : 788 - 794
  • [22] Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI)
    Misaki, Kenta
    Tanaka, Eiichi
    Inoue, Eisuke
    Tamura, Naoto
    Hirano, Fuminori
    Taniguchi, Yoshinori
    Sato, Hiroshi
    Naniwa, Taio
    Oshikawa, Hideto
    Yoshitama, Tamami
    Takakubo, Yuya
    Suzuki, Yoko
    Himeno, Shinkichi
    Tsuritani, Katsuki
    Matsumoto, Shigeru
    Yamanaka, Hisashi
    Harigai, Masayoshi
    MODERN RHEUMATOLOGY, 2024, : 17 - 26
  • [23] Results. - Sixteen patients were included (9 women and 7 men). They had recurrent anterior uveitis (n=10), recurrent scleritis (n=5) and intermediate uveitis. Opthalmological involvement was neither severe nor complicated. All patients combined, the annual relapse ratio (ARR) decreased from 1.8 (0.8-3.5) to 0.3 (0-1.6), (P=0.06). Colchicine was considered effective in three of 10 analyzable patients. In only one patient, treatment was stopped for adverse effects after six weeks. Conclusion. - In view of the interesting benefit-risk ratio of colchicine, it seems appropriate to focus on this molecule in non-granulomatous anterior uveitis and non-severe recurrent scleritis. © 2022 Socie acute accent te acute accent Nationale Franc , aise de Me acute accent decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
    Rogier, T.
    Auvens, C.
    Thibault, T.
    Mouries-Martin, S.
    Muller, G.
    El Hssaini, N.
    Turcu, A.
    Besancenot, J. -f.
    Bielefeld, P.
    Devilliers, H.
    REVUE DE MEDECINE INTERNE, 2022, 43 (11): : 640 - 644
123